414
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial

, , , , &
Pages 762-764 | Received 24 Sep 2021, Accepted 26 Oct 2021, Published online: 08 Nov 2021
 

Acknowledgments

Medical writing assistance was provided by Shelley Batts, PhD, an employee of Analysis Group, Inc. and funded by the study sponsor.

Disclosure statement

Bhavik J. Pandya, Andy Garnham, and Manasee V. Shah are employees of Astellas and hold stock/options. Cynthia Z. Qi and Hongbo Yang are employees of Analysis Group, Inc., which has received consulting fees from Astellas for this study. Amer M. Zeidan is a consultant for Astellas and has received honoraria and research funding.

Additional information

Funding

This study was funded by Astellas Pharma, Inc.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.